toggle visibility Search & Display Options

Select All    Deselect All
 |   | 

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/acutrialsocom/public_html/refbase-ocom/includes/ on line 5275
  Record Links
Author (up) Zhenzhong, L.; Xiaojun, Y.; Weijun, T.; Yuehua, C.; Jie, S.; Jimeng, Z.; Anqi, W.; Chunhui, B.; Yin, S. url  doi
  Title Comparative effect of electroacupuncture and moxibustion on the expression of substance P and vasoactive intestinal peptide in patients with irritable bowel syndrome Type of Study RCT
  Year 2015 Publication Journal of Traditional Chinese Medicine = Chung i tsa Chih Ying wen pan / Sponsored by All-China Association of Traditional Chinese Medicine, Academy of Traditional Chinese Medicine Abbreviated Journal J Tradit Chin Med  
  Volume 35 Issue 4 Pages 402-410  
  Keywords AcuTrials; Gastrointestinal Diseases; Irritable Bowel Syndrome; IBS; RCT; Acu Versus CAM Control; Colonic Mucosa; Neuropeptide Substance P; Vasoactive Intestinal Peptide; Immunohistochemistry Assay; Colonoscopy; Fixed Acupuncture Protocol; Restricted Modalities, Acupuncture Only; CAM Control; Moxibustion; Moxa; Electroacupuncture  
  Abstract OBJECTIVE: To compare the impacts of electroacupuncture (EA) and moxibustion (Mox) on the primary gastrointestinal symptoms and the expressions of colonic mucosa-associated neuropeptide substance P (SP) and vasoactive intestinal peptide (VIP) in patients with either diarrhea-predominant or constipation-predominant irritable bowel syndrome (IBS-D and IBS-C, respectively). METHODS: Eighty-five IBS patients were randomly allocated to the EA and Mox groups. Zusanli (ST 36) and Shangjuxu (ST 37) were selected as acupoints for electroacupuncture or warm moxibustion treatment once a day for 14 consecutive days. Before and after the treatment sessions, a Visual Analog Pain Scale and the Bristol Stool Form Scale were used to evaluate gastrointestinal symptoms. There were four dropout cases, leaving 81 participants (41 with IBS-D and 40 with IBS-C) who volunteered to undergo colonoscopy before and after the treatment sessions. During colonoscopy, sigmoid mucosa were collected to detect SP and VIP expression using immunohistochemistry assay. RESULTS: Both EA and Mox treatments were effective at relieving abdominal pain in IBS-D and IBS-C patients. However, Mox was more effective at reducing diarrhea in IBS-D patients, whereas EA was more effective at improving constipation in IBS-C patients. EA and Mox treatments both down-regulated the abnormally increased SP and VIP expression in the colonic mucosa, with no significant difference shown between the two treatments. CONCLUSION: Both EA and Mox treatments are effective at ameliorating gastrointestinal symptoms by reducing SP and VIP expression in the colonic mucosa of IBS patients.  
  Address Department of Physical Therapy and Acupuncture, Jinhua Hospital of Zhejiang University, Jinhua 321000, China  
  Language English Number of Treatments 14  
  Treatment Follow-up Frequency >1/WK Number of Participants 85  
  Time in Treatment 2 weeks Condition Irritable Bowel Syndrome
  Disease Category Gastrointestinal Diseases OCSI Score  
  Notes PMID:26427109 Approved yes  
  Call Number OCOM @ refbase @ Serial 1923  
Permanent link to this record
Select All    Deselect All
 |   | 

Save Citations:
Export Records: